SSEA-3 Positive Stress-Enduring Stem Cells (MUSE)

What are SSEA-3 positive stress-enduring cells?

Inside the body's ordinary stem cell populations hides a small, unusual subset. First characterized in adult human mesenchymal populations and reported in PNAS in 2010, these cells are identified by a surface marker called SSEA-3 and are known in the research literature as MUSE cells, short for Multilineage-differentiating Stress-Enduring cells. The name says it plainly: they endure stress that kills other cells, and they can give rise to cell types from all three germ layers, the building blocks of skin and nerve, muscle and bone, and internal organs.

That combination is rare. Pluripotent-like flexibility usually comes packaged with a safety problem, because primitive cells that can become anything can also form tumors. In the foundational work, these cells did not: injected into immunodeficient mice, they formed no teratomas. A naturally occurring cell with broad differentiation capacity and no tumor formation in the foundational studies is exactly the profile regenerative medicine has been hunting for, which is why a small field has grown up around them.

How do they work?

The most interesting part is that the body already uses them. A 2018 review framed these cells as endogenous reparative stem cells: a built-in repair reserve. In a healthy steady state, small numbers circulate from the bone marrow through the blood into the connective tissue of nearly every organ. After serious damage, a heart attack or a stroke, their numbers in the bloodstream rise sharply within about a day.

They find the damage through a specific homing signal. Injured tissue releases a molecule called sphingosine-1-phosphate, and these cells carry the matching receptor, the S1P-S1PR2 axis, so they are drawn preferentially toward the injury. Once there, they contribute two ways: differentiating into the local cell types the tissue needs, and releasing anti-inflammatory, anti-fibrotic, and cell-protective signals that stabilize the neighborhood. Ordinary MSCs do the signaling half of that job; the differentiation half is what sets this subset apart in the animal work.

Why they matter in regenerative medicine

Three properties explain the excitement. First, the range: cells that can produce all three germ layers address damage that signaling alone may not. Second, the safety profile in the foundational work, because non-tumorigenic pluripotent-like behavior removes the classic deal-breaker of more primitive cells. Third, the stress endurance itself, which is not just a survival trick. Selecting cells for surviving stress is also a manufacturing logic: the harsh conditions of isolation, culture, and infusion filter out fragile cells, and this population comes pre-filtered.

The honest counterweight: the field is young and small. Most of the evidence is preclinical, and the human trials so far are the first small ones rather than settled results.

What the studies show

The heart work is the most detailed mechanistically. In a 2018 study in Circulation Research using a rabbit model of heart attack, treatment reduced infarct size by roughly half and raised ejection fraction by about 38 percent versus vehicle at two months, and the donor cells kept working for up to six months without immunosuppression. A rabbit model, not people, and a striking result within that limit.

The stroke line runs from lab to clinic. A 2016 study documented these cells mobilizing into the blood of 29 stroke patients, direct evidence the homing response happens in people. Animal studies in 2017 and 2020 showed engraftment, differentiation into neurons, and improved recovery, with no tumors over follow-up of up to ten months. Then the human step: a 2023 randomized, double-blind, placebo-controlled trial gave a single intravenous dose of the allogeneic cell product CL2020 two to four weeks after ischemic stroke, without immunosuppression and without donor matching. At 12 weeks, 40 percent of treated patients reached a good functional outcome against 10 percent on placebo. A small trial, and the authors call for larger study, but it is the kind of controlled human signal most cell therapies never produce this early.

A completed Phase 1 trial in Japan (the SHIELD study, NCT04261335) also tested CL2020 in newborns with oxygen-deprivation brain injury to establish safety and dosing, and reviews describe the same reparative behavior being explored in lung, liver, kidney, skin, and cartilage models.

The pros and the cons

Why the evidence lags the interest

This is a young field concentrated in a handful of research groups, most prominently in Japan, and clinical-grade manufacturing of a rare cell subset is specialized work. Trials therefore arrive one at a time rather than in waves. The animal and mechanism base has run well ahead of the human program, which is normal for a cell therapy at this stage: the stroke trial above is the template for what comes next, and larger confirmation is the missing piece rather than new ideas.

What the key studies tested

Our framing rule for evidence: a study tests one preparation, at one dose, on one schedule, in one model or population. Where the evidence sits:

Every study behind this article is filterable in our research library on the Science page.

Questions people ask

This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. MUSE Cells is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.